Results 81 to 90 of about 7,389,456 (292)
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
BiomoleculesViral infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with delayed immune reconstitution or prolonged immunosuppression.
Eva M. Weissinger +4 more
doaj +1 more source
Molecular Oncology, EarlyView.Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou +4 more
wiley +1 more source
Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation
Frontiers in Immunology, 2019 Delayed immune reconstitution and the consequently high rates of leukemia relapse and infectious complications are the main limitations of haploidentical hematopoietic stem cell transplantation.
Ping Zhang +3 more
doaj +1 more source
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Molecular Oncology, EarlyView.Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
Molecular Oncology, EarlyView.How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
High-throughput screening for optimizing adoptive T cell therapies
Experimental Hematology & OncologyAdoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-
Yuchen Zhang +5 more
doaj +1 more source
Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients
Egyptian Journal of Medical Human GeneticsBackground Natural killer (NK) cells are crucial constituents of innate immunity, playing a vital role in the early defense against viral infections and cancer.
Abdulaziz Alamri
doaj +1 more source
Engineering T cells to overcome the hostile tumour microenvironment [PDF]
, 2015 Adoptive immunotherapy with autologous T lymphocytes transduced with anti-tumour antigen-specific T cell receptors (TCRs) has emerged as a promising anti-cancer therapy.
Alvares, B
core
Use of biological therapy to enhance both virotherapy and adoptive t-cell therapy for cancer
, 2008 To protect viral particles from neutralization, sequestration, nonspecific adhesion, and mislocalization following systemic delivery, we have previously exploited the natural tumor-homing properties of antigen-specific CD8+ T cells.
Willmon, Candice +29 more
core +1 more source